Based on effect sizes, a numerical trend toward greater efficacy was also observed on each of the newly defined subscales in rivastigmine-treated patients compared with placebo.
← all excerpts
Rivastigmine in moderately severe-to-severe Alzheimer's disease: Severe Impairment Battery factor analysis.
2
—
—
The sentences
Despite an apparent trend towards reduced decline in rivastigmine-treated patients compared with placebo on the visual (Factor 1), language (Factor 2), praxis and social skills (Factor 4), and naming (Factor 5) subscales, these differences did not reach significance ( P = 0.056, P = 0.056, P = 0.117 and P = 0.072, respectively; Figure 1 ).